Rivaroxaban (Xarelto®) for the Prevention of Stroke in Atrial Fibrillation

Assessment Status Assessment Process Complete
Drug Rivaroxaban
Brand Xarelto®
Indication For the prevention of stroke in atrial fibrillation.
Assessment Process
Rapid review commissioned 17/08/2011
Rapid review completed 31/08/2011
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 11/11/2021
NCPE assessment completed 02/04/2012
NCPE assessment outcome Reimbursement not Recommended

The NCPE do not believe that rivaroxaban is cost effective for this indication at the submitted price.

Technical Summary


Following the NCPE pharmacoeconomic assessment (2/4/2012) the manufacturer reduced the price of rivaroxaban (23/5/2012).  At this revised price we now consider rivaroxaban cost effective for this indication.  A positive recommendation was made on the 19/06/2012.